Ximena Lopez-Lorenzo, David Hueting, Eliott Bosshard and Per-Olof Syrén
{"title":"PET 酶将 PET 微塑料颗粒在人血清中降解为单体","authors":"Ximena Lopez-Lorenzo, David Hueting, Eliott Bosshard and Per-Olof Syrén","doi":"10.1039/D4FD00014E","DOIUrl":null,"url":null,"abstract":"<p >More than 8 billion tons of plastic waste has been generated, posing severe environmental consequences and health risks. Due to prolonged exposure, microplastic particles are found in human blood and other bodily fluids. Despite a lack of toxicity studies regarding microplastics, harmful effects for humans seem plausible and cannot be excluded. As small plastic particles readily translocate from the gut to body fluids, enzyme-based treatment of serum could constitute a promising future avenue to clear synthetic polymers and their corresponding oligomers <em>via</em> their degradation into monomers of lower toxicity than the material they originate from. Still, whereas it is known that the enzymatic depolymerization rate of synthetic polymers varies by orders of magnitude depending on the buffer and media composition, the activity of plastic-degrading enzymes in serum was unknown. Here, we report how an engineered PETase, which we show to be generally <em>trans</em>-selective <em>via</em> induced fit docking, can depolymerize two different microplastic-like substrates of the commodity polymer polyethylene terephthalate (PET) into its non-toxic monomer terephthalic acid (TPA) alongside mono(2-hydroxyethyl)terephthalate (MHET) in human serum at 37 °C. We show that the application of PETase does not influence cell viability <em>in vitro</em>. Our work highlights the potential of applying biocatalysis in biomedicine and represents a first step towards finding a future solution to the problem that microplastics in the bloodstream may pose.</p>","PeriodicalId":49075,"journal":{"name":"Faraday Discussions","volume":"252 ","pages":" 387-402"},"PeriodicalIF":3.4000,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2024/fd/d4fd00014e?page=search","citationCount":"0","resultStr":"{\"title\":\"Degradation of PET microplastic particles to monomers in human serum by PETase†\",\"authors\":\"Ximena Lopez-Lorenzo, David Hueting, Eliott Bosshard and Per-Olof Syrén\",\"doi\":\"10.1039/D4FD00014E\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >More than 8 billion tons of plastic waste has been generated, posing severe environmental consequences and health risks. Due to prolonged exposure, microplastic particles are found in human blood and other bodily fluids. Despite a lack of toxicity studies regarding microplastics, harmful effects for humans seem plausible and cannot be excluded. As small plastic particles readily translocate from the gut to body fluids, enzyme-based treatment of serum could constitute a promising future avenue to clear synthetic polymers and their corresponding oligomers <em>via</em> their degradation into monomers of lower toxicity than the material they originate from. Still, whereas it is known that the enzymatic depolymerization rate of synthetic polymers varies by orders of magnitude depending on the buffer and media composition, the activity of plastic-degrading enzymes in serum was unknown. Here, we report how an engineered PETase, which we show to be generally <em>trans</em>-selective <em>via</em> induced fit docking, can depolymerize two different microplastic-like substrates of the commodity polymer polyethylene terephthalate (PET) into its non-toxic monomer terephthalic acid (TPA) alongside mono(2-hydroxyethyl)terephthalate (MHET) in human serum at 37 °C. We show that the application of PETase does not influence cell viability <em>in vitro</em>. Our work highlights the potential of applying biocatalysis in biomedicine and represents a first step towards finding a future solution to the problem that microplastics in the bloodstream may pose.</p>\",\"PeriodicalId\":49075,\"journal\":{\"name\":\"Faraday Discussions\",\"volume\":\"252 \",\"pages\":\" 387-402\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-03-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://pubs.rsc.org/en/content/articlepdf/2024/fd/d4fd00014e?page=search\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Faraday Discussions\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://pubs.rsc.org/en/content/articlelanding/2024/fd/d4fd00014e\",\"RegionNum\":3,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Chemistry\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Faraday Discussions","FirstCategoryId":"92","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/fd/d4fd00014e","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Chemistry","Score":null,"Total":0}
引用次数: 0
摘要
产生的塑料废物超过 80 亿吨,对环境造成了严重后果,并对健康构成了威胁。由于长期接触,在人体血液和其他体液中发现了微塑料颗粒。尽管缺乏有关微塑料毒性的研究,但其对人体的有害影响似乎是可信的,而且不能排除。由于小塑料微粒很容易从肠道转移到体液中,因此对血清进行酶处理可能是未来清除合成聚合物及其响应低聚物的一个很有前景的途径,方法是将其降解为毒性低于其来源材料的单体。不过,尽管人们知道合成聚合物的酶解聚率因缓冲液和培养基成分的不同而有数量级的差异,但塑料降解酶在血清中的活性却不为人知。在这里,我们报告了一种工程 PET 酶是如何在 37°C 的人体血清中将商品聚合物聚对苯二甲酸乙二醇酯(PET)的两种不同微塑料基质快速解聚成其无毒单体对苯二甲酸(TPA)和对苯二甲酸单(2-羟乙基)酯(MHET)的。我们的研究表明,应用 PETase 不会影响体外细胞的活力。我们的工作彰显了将生物催化技术应用于生物医学的潜力,并为未来解决血液中的微塑料可能带来的问题迈出了第一步。
Degradation of PET microplastic particles to monomers in human serum by PETase†
More than 8 billion tons of plastic waste has been generated, posing severe environmental consequences and health risks. Due to prolonged exposure, microplastic particles are found in human blood and other bodily fluids. Despite a lack of toxicity studies regarding microplastics, harmful effects for humans seem plausible and cannot be excluded. As small plastic particles readily translocate from the gut to body fluids, enzyme-based treatment of serum could constitute a promising future avenue to clear synthetic polymers and their corresponding oligomers via their degradation into monomers of lower toxicity than the material they originate from. Still, whereas it is known that the enzymatic depolymerization rate of synthetic polymers varies by orders of magnitude depending on the buffer and media composition, the activity of plastic-degrading enzymes in serum was unknown. Here, we report how an engineered PETase, which we show to be generally trans-selective via induced fit docking, can depolymerize two different microplastic-like substrates of the commodity polymer polyethylene terephthalate (PET) into its non-toxic monomer terephthalic acid (TPA) alongside mono(2-hydroxyethyl)terephthalate (MHET) in human serum at 37 °C. We show that the application of PETase does not influence cell viability in vitro. Our work highlights the potential of applying biocatalysis in biomedicine and represents a first step towards finding a future solution to the problem that microplastics in the bloodstream may pose.